Titan Pharmaceuticals, Inc. (de)
NASDAQ:TTNP
| Market Cap (Intraday) | 24.86M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.52 |
| 50-Day MA | $2.45 |
| 200-Day MA | $3.53 |
Titan Pharmaceuticals, Inc. (de) Stock, NASDAQ:TTNP
400 Oyster Point Boulevard, Suite 505, South San Francisco, California 94080-1958
United States of America
Phone: +1.650.244.4990
Number of Employees: 12
Description
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.